International Conference on Haemophilus influenzae type b infection in Asia. Bali, IDN, 1996/12/17.
To scrutinize the experiences of those European countries that have played a central role in understanding the behavior of and vaccination for Haemophilus influenzae type b (Hib) diseases, to enlighten weaknesses and to explore whether lessons learned would benefit other countries in combating Hib.
Epidemiologic and clinical data on Hib infections and vaccinations were analyzed, including all disease manifestations and all age groups.
To improve reliability, sources that used active case finding were especially searched for.
In the prevaccination era meningitis represented 40 to 70% of all classical Hib diseases.
Epiglottitis was the second most common presentation, except in southern Europe (data not available from former socialist countries).
The overall incidence of meningitis and of all Hib disease combined for children ages 0 to 4 years was 23 and 41 per 100 000, suggesting 9900 and 17 800 cases per year, respectively.
Including all age groups and entities,>20 000 Hib cases occurred annually.
Vaccination, accomplished with two or three primary doses and a late booster, has almost eliminated Hib disease in>10 countries, and>10 000 cases per year are prevented.
An age analysis of Hib meningitis suggests that strong early immunogenicity is not as imperative in Europe as in some other regions.
The incidence of non-type b H. influenzae infections has not increased. (...)
Mots-clés Pascal : Haemophilus influenzae, Pasteurellaceae, Bactérie, Bactériose, Infection, Localisation, Méningite, Epiglottite, Pneumonie, Incidence, Epidémiologie, Efficacité, Prévention, Immunoprophylaxie, Nourrisson, Homme, Enfant, Système nerveux pathologie, Système nerveux central pathologie, ORL pathologie, Appareil respiratoire pathologie, Haemophilus influenzae type b
Mots-clés Pascal anglais : Haemophilus influenzae, Pasteurellaceae, Bacteria, Bacteriosis, Infection, Localization, Meningitis, Epiglottitis, Pneumonia, Incidence, Epidemiology, Efficiency, Prevention, Immunoprophylaxis, Infant, Human, Child, Nervous system diseases, Central nervous system disease, ENT disease, Respiratory disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0032017
Code Inist : 002B05A02. Création : 31/05/1999.